NeuroPointDX news
Only a few years ago, leading autism expert David Amaral described the disorder as a lifelong disability. Today, he acknowledges that description is no longer true. “Research lately shows that a substantial proportion of children with autism spectrum disorder (ASD)—something on the order of 30%—show really substantial improvements in their autism symptoms,” says Amaral, founding research director of the
In a paper published online this week in Autism Research, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and academic and clinical institutions across
Continued analysis of samples from the Children’s Autism Metabolome Project (CAMP), the most comprehensive clinical study of metabolism in children who have autism spectrum disorder (ASD) conducted to date, has identified three new areas of metabolism that affect the biology of children with ASD. These include biomarkers indicating that altered neurotransmission, energy metabolism, and purine metabolism may be associated
Video of presentation at The National TACA Autism Conference – East Coast in Atlanta, Georgia, March 2019.
In this video, Beth Donley shares her history as an autism mom as well as details about the NeuroPointDX NPDX ASD t
NeuroPointDX, a business unit of Stemina Biomarker Discovery, today announced the company will present recent data from the Children’s Autism Metabolome Project (CAMP), its large, comprehensive clinical study, supporting its precision medicine approach to the diagnosis and treatment of autism spectru